In a previous study, we demonstrated that CD4+ T cell immunity in the peripheral blood before therapy predicted the antitumor efficacy of second-line nivolumab therapy in patients with non-small cell lung cancer (NSCLC). The gene discussed is CD4; the disease is non-small cell lung carcinoma.